This protocol covers the management of hypopituitarism in adult patients in whom growth hormone deficiency has been confirmed and no contraindications to replacement are present.
The patient is an adult with proven growth hormone deficiency (GHD) and no contraindications — the population for whom GH replacement is recommended by current evidence-based guidance.
Management centres on growth hormone (GH) replacement therapy, with the approach adjusted based on patient age and ongoing clinical response. The full dosing algorithm, titration schedule, and decision points are in the complete protocol.
The primary biochemical goal is keeping serum IGF-1 levels below the upper limit of normal throughout the course of therapy.